Eris Lifesciences (ERIS) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 consolidated revenue reached INR 720 crore, up 54.2% year-over-year, driven by acquisitions, organic growth, and expansion into super specialty segments.

• EBITDA grew 47% to INR 250 crore, with margin at 34.7%, and net profit was INR 89 crore, reflecting higher amortization, finance costs, and tax rate.

• Integration of Biocon and Swiss Parenterals businesses completed ahead of schedule, contributing to revenue and margin expansion.

• Major acquisitions included 19% of Swiss Parenterals and the Indian Branded Formulations business from Biocon Biologics; binding term sheet signed to acquire 100% of Chemman Labs.

• Composite scheme of arrangement for amalgamation of Eris Oaknet Healthcare Private Limited with the company approved.

Financial highlights

• Domestic Branded Formulations (DBF) contributed 90% of Q1 revenue, with organic revenue growth of 10% and gross margin at 86%.

• Gross margin declined 829 bps to 74.9% due to product/business mix shift; fixed expenses as a percentage of revenue fell 663 bps year-over-year.

• Operating cash flow was 70% of EBITDA; cash EPS grew 10.3% to INR 9.5.

• Net debt as of June 30 was INR 2,737 crore.

• Standalone revenue from operations for Q1 FY25 was ₹449.17 crore, up from ₹332.25 crore in Q1 FY24.

Outlook and guidance

• FY25 consolidated revenue expected to exceed INR 3,000 crore with 35% EBITDA margin; DBF revenue guided at INR 2,600+ crore with 36-37% EBITDA margin.

• Biocon business revenue guided at INR 585 crore (30% EBITDA margin); Swiss Parenterals at INR 330 crore (35% EBITDA margin).

• Capex planned at INR 100-120 crore for hormones, insulins, and MABS; OCF/EBITDA ratio expected at 70-75%.

• Net debt targeted to reduce to INR 2,000 crore by FY26; effective tax rate expected to gradually decline from 25% to 18%-19% over the next 3-4 years.

• The company is expanding its capabilities in biological products through the acquisition of Chemman Labs.